Brenntag Pharma and Evonik REXIM Sign Strategic Distribution Partnership for Pharmaceutical-Grade Amino Acids

A young woman pours magnesium nutritional supplement into a glass of water.

(IN BRIEF) Brenntag Pharma has signed a strategic partnership with Evonik REXIM for the exclusive distribution of REXIM® GMP-grade amino acids across most of Europe. The agreement took effect on 1 July 2026 and covers regions including DACH, the UK, France, Benelux, Scandinavia, Central and Eastern Europe, Israel and Turkey, while excluding Italy, Ukraine, the Middle East and Africa. The partnership strengthens Brenntag’s role in the biopharma and API markets by expanding access to high-quality amino acids used in medical nutrition, pharmaceutical APIs, excipients and cell culture media for biopharmaceutical applications. Evonik REXIM brings expertise in fermentation, bioconversion and synthetic-based amino acid manufacturing, while Brenntag contributes regional distribution reach, technical capabilities, customer relationships and regulatory know-how. Both companies said the collaboration will support supply security, market development and innovation in pharmaceutical and biopharmaceutical manufacturing.

(PRESS RELEASE) ESSEN, 15-Jul-2026 — /EuropaWire/ — Brenntag Pharma has signed a strategic partnership with Evonik REXIM for the exclusive distribution of REXIM® pharmaceutical-grade amino acids to pharmaceutical and biopharmaceutical customers across most of Europe.

The agreement, effective from 1 July 2026, strengthens Brenntag’s position in the biopharma and active pharmaceutical ingredient markets by expanding its portfolio of high-quality GMP-grade amino acids.

Under the partnership, Brenntag will assume responsibility for market development and distribution across a broad European territory, including the DACH region, the United Kingdom, France, Benelux, Scandinavia, Central and Eastern Europe, Israel, Turkey and other markets. Italy, Ukraine, the Middle East and Africa are excluded from the agreement.

Amino acids are essential components of proteins and play a central role in biochemical and metabolic processes. REXIM® offers highly purified natural and non-natural amino acids and derivatives designed for regulated applications.

These ingredients are used in several pharmaceutical and biopharmaceutical areas, including medical nutrition, pharmaceutical active ingredients, excipients and nutrients for cell culture media in biopharma manufacturing.

Evonik REXIM is a leading supplier of high-quality amino acids and provides relevant parts of production from domestic European supplies. The company combines expertise in fermentation, bioconversion and synthetic-based manufacturing.

The collaboration with Brenntag supports Evonik REXIM’s strategy to expand its presence in key global markets while giving customers stronger local service, technical support and long-term supply security.

Joakim Rehné, President Brenntag Pharma EMEA, said the partnership reflects Brenntag’s commitment to bringing high-value pharmaceutical ingredients and solutions closer to customers.

“By combining Evonik’s world-class expertise in GMP amino acids with Brenntag’s extensive market presence, technical capabilities, and regulatory know-how, we are uniquely positioned to support the evolving needs of pharmaceutical and biopharmaceutical manufacturers across the region,” said Rehné.

He added that the partnership will create a stronger and more reliable supply network, helping accelerate innovation and support patient access to critical therapies.

Thomas Hermann, Head of the REXIM® product line at Evonik Health Care, said the collaboration will significantly expand Evonik REXIM’s market reach.

“Brenntag’s strong regional footprint, deep customer relationships, and extensive experience in the life-science sector make them an ideal partner,” said Hermann.

He added that the companies will work together to provide customers with reliable access to high-quality GMP amino acids and support the growth of the pharmaceutical and biopharmaceutical markets.

About Evonik:
Evonik is a global chemical company, headquartered in Essen, Germany, active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The common motivation of the approximately 31,000 employees is to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people’s lives. In all markets. Every day. For more on Evonik and the REXIM® product range visit: https://healthcare.evonik.com/en/biopharma/amino-acids/rexim-portfolio

About Brenntag:
Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 17,300 employees worldwide and operates a network of around 600 sites in more than 70 countries. In 2025, Brenntag generated sales of 15.2 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 30 ESG and DAX ESG Target. For more information, visit https://brenntag.com

Media Contact:

Helmut Weintögl
Brenntag SE
Communications EMEA
Telephone: +49 (201) 6496-1339
E-Mail: global.communications@brenntag.com
www.brenntag.com

SOURCE: Brenntag SE